Arbejdsmarkedets Tillaegspension Invests $23.29 Million in Cencora, Inc. $COR

Posted by Brenda Bartman on May 16th, 2026

Arbejdsmarkedets Tillaegspension bought a new position in shares of Cencora, Inc. (NYSE:COR – Free Report) during the 4th quarter, HoldingsChannel reports. The firm bought 68,958 shares of the company’s stock, valued at approximately $23,291,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Oakworth Capital Inc. bought a new position in shares of Cencora during the 4th quarter valued at about $26,000. Archer Investment Corp grew its stake in shares of Cencora by 134.3% in the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after acquiring an additional 47 shares during the last quarter. Optima Capital LLC bought a new stake in shares of Cencora in the 4th quarter worth $31,000. IAG Wealth Partners LLC purchased a new stake in Cencora during the third quarter valued at $30,000. Finally, Cloud Capital Management LLC bought a new position in Cencora in the 3rd quarter worth $31,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Stock Down 1.6%

COR stock opened at $256.96 on Friday. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59. The firm has a market capitalization of $49.99 billion, a PE ratio of 19.71, a P/E/G ratio of 1.20 and a beta of 0.64. The company’s 50 day simple moving average is $314.65 and its 200-day simple moving average is $339.22. Cencora, Inc. has a 12 month low of $244.82 and a 12 month high of $377.54.

Cencora (NYSE:COR – Get Free Report) last issued its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.07). The firm had revenue of $78.36 billion during the quarter, compared to analysts’ expectations of $81.09 billion. Cencora had a return on equity of 135.20% and a net margin of 0.78%.The company’s quarterly revenue was up 3.9% compared to the same quarter last year. During the same period last year, the business posted $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Equities analysts expect that Cencora, Inc. will post 17.76 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 1st. Shareholders of record on Friday, May 15th will be given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Friday, May 15th. Cencora’s dividend payout ratio is presently 18.40%.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. JPMorgan Chase & Co. increased their price objective on shares of Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a research report on Tuesday, February 10th. Robert W. Baird dropped their target price on Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Morgan Stanley set a $342.00 price target on shares of Cencora in a research note on Friday, May 8th. William Blair assumed coverage on Cencora in a research report on Tuesday, April 28th. They issued a “market perform” rating for the company. Finally, Leerink Partners reissued an “outperform” rating on shares of Cencora in a research note on Tuesday, March 17th. Twelve investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $380.25.

Read Our Latest Analysis on COR

Cencora Profile

(Free Report)

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.

Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR – Free Report).

Institutional Ownership by Quarter for Cencora (NYSE:COR)

Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.